Epirium Bio reports positive Phase 1 results for MF-300 in healthy volunteers

Epirium Bio, a clinical-stage biopharmaceutical company, announced positive Phase 1 clinical trial results for MF-300, a first-in-class oral 15-PGDH enzyme inhibitor in development for sarcopenia. According to the company, the trial met its primary safety endpoint, with MF-300 generally well tolerated across all doses and no participant discontinuations. The randomized, double-blind, placebo-controlled trial included 70 […] The post Epirium Bio reports positive Phase 1 results for MF-300 in healthy volunteers appeared first on Longevity.Technology.